{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:34:32Z","timestamp":1791340472225,"version":"4.3.1"},"reference-count":18,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,11,4]],"date-time":"2008-11-04T00:00:00Z","timestamp":1225756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Anaplastic large cell lymphoma (ALCL) is characterized by advanced disease at presentation (70\u201380% of pediatric cases) and accounts for 10\u201315% of all childhood lymphomas. Treatment strategies for pediatric ALCL vary from short pulse B\u2010NHL chemotherapy to prolonged leukemia like therapy. The optimal treatment strategy is unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>CCG\u20105941 used a compressed aggressive multiagent T\u2010cell lineage chemotherapy regimen consisting of a 3\u2010week induction therapy (vincristine, prednisone, cyclophosphamide, daunomycin, asparaginase) followed by a 3\u2010week consolidation period (vincristine, prednisone, etoposide, 6\u2010thioguanine, cytarabine, asparaginase, methotrexate) followed by six courses of maintenance chemotherapy at 7\u2010week intervals (cyclophosphamide, 6\u2010thioguanine, vincristine, prednisone, doxorubicin, asparaginase, methotrexate etoposide, cytarabine). Total therapy was 48 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eighty\u2010six children (male 56%, female 44%) with non\u2010localized ALCL (CD30+) were treated. The majority of tumors were positive for ALK (90%) and of T lineage (83%). Extranodal disease was common (mediastinum 35%, skin 15%, lung 14%, bone 12%, bone marrow 13%, liver 6%, and other viscera 17%). Grade 4 neutropenia occurred in 82% of patients. The 5\u2010year EFS was 68% (95% CI of 57\u201378%) and the 5\u2010year OS was 80% (95% CI of 69\u201387%). There were 21 relapses and 4 toxic deaths as first events. Relapse occurred early with 17 (81%) relapses occurring within 2 years of diagnosis and 12 (57%) while receiving therapy. Univariate analysis for risk factors only identified bone marrow involvement predicting lower EFS (<jats:italic>P<\/jats:italic>\u2009=\u20090.03).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>CCG\u20105941 demonstrated efficacy similar to previously reported regimens but with significant hematologic toxicity. Pediatr Blood Cancer 2009;52:335\u2013339. \u00a9 2008 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.21817","type":"journal-article","created":{"date-parts":[[2008,11,4]],"date-time":"2008-11-04T21:46:06Z","timestamp":1225835166000},"page":"335-339","source":"Crossref","is-referenced-by-count":105,"title":["Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: Final results of children's cancer group study 5941"],"prefix":"10.1002","volume":"52","author":[{"given":"Eric J.","family":"Lowe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sposto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrie L.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Finlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Zwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minnie","family":"Abromowitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,1,8]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605093341906"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.12.3699"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V66.4.848.848"},{"key":"e_1_2_5_5_2","volume-title":"Pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-100958"},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood.V84.8.2467.2467","article-title":"Clinicopathologic features and treatment outcome of children with large\u2010cell lymphoma and the t(2;5)(p23;q35)","volume":"84","author":"Sandlund JT","year":"1994","journal-title":"Blood"},{"key":"e_1_2_5_8_2","first-page":"3591","article-title":"CD30(+) anaplastic large\u2010cell lymphoma in children: Analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology","volume":"92","author":"Brugieres L","year":"1998","journal-title":"Blood"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.075"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21438"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03482.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2291"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05808.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.9.3727"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.11.3913"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.5.895"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403888"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-066852"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008352726155"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.21817","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.21817","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T01:01:54Z","timestamp":1695949314000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.21817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,8]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1002\/pbc.21817"],"URL":"https:\/\/doi.org\/10.1002\/pbc.21817","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,8]]}}}